{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:35:42Z","timestamp":1792427742474,"version":"4.5.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T00:00:00Z","timestamp":1551484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40268-019-0263-2","type":"journal-article","created":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T06:02:11Z","timestamp":1551506531000},"page":"227-234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Ulcerative Colitis: Shifting Sands"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2784-4046","authenticated-orcid":false,"given":"Geert R. A. M.","family":"D\u2019Haens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3353-9590","authenticated-orcid":false,"given":"James O.","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-940X","authenticated-orcid":false,"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,2]]},"reference":[{"key":"263_CR1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/00365521.2016.1256425","volume":"52","author":"G Huppertz-Hauss","year":"2017","unstructured":"Huppertz-Hauss G, H\u00f8ivik ML, Jelsness-J\u00f8rgensen LP, Opheim R, Henriksen M, H\u00f8ie O, et al. Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study. Scand J Gastroenterol. 2017;52:351\u20138.","journal-title":"Scand J Gastroenterol."},{"key":"263_CR2","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","volume":"380","author":"I Ord\u00e1s","year":"2012","unstructured":"Ord\u00e1s I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380:1606\u201319.","journal-title":"Lancet."},{"key":"263_CR3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","volume":"13","author":"HS Souza de","year":"2016","unstructured":"de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13\u201327.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"263_CR4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4292\/wjgpt.v7.i1.112","volume":"7","author":"E Legaki","year":"2016","unstructured":"Legaki E, Gazouli M. Influence of environmental factors in the development of inflammatory bowel diseases. World J Gastrointest Pharmacol Ther. 2016;7:112\u201325.","journal-title":"World J Gastrointest Pharmacol Ther."},{"key":"263_CR5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev-pathol-012615-044152","volume":"11","author":"TC Liu","year":"2016","unstructured":"Liu TC, Stappenbeck TS. Genetics and pathogenesis of inflammatory bowel disease. Annu Rev Pathol. 2016;11:127\u201348.","journal-title":"Annu Rev Pathol."},{"key":"263_CR6","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/01.mib.0000179467.01748.99","volume":"11","author":"T Bernklev","year":"2005","unstructured":"Bernklev T, Jahnsen J, Lygren I, Henriksen M, Vatn M, Moum B. Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis. 2005;11:909\u201318.","journal-title":"Inflamm Bowel Dis."},{"key":"263_CR7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/apt.13852","volume":"45","author":"BG Feagan","year":"2017","unstructured":"Feagan BG, Patel H, Colombel JF, Rubin DT, James A, Mody R, et al. Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial. Aliment Pharmacol Ther. 2017;45:264\u201375.","journal-title":"Aliment Pharmacol Ther."},{"key":"263_CR8","first-page":"58","volume":"4","author":"J Pan\u00e9s","year":"2015","unstructured":"Pan\u00e9s J, Louis E, Rutgeerts P. The full picture of ulcerative colitis: the burden, the patient, the treatment. EMJ Gastroenterol. 2015;4:58\u201365.","journal-title":"EMJ Gastroenterol."},{"issue":"46\u201354","key":"263_CR9","first-page":"e42","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(46\u201354):e42.","journal-title":"Gastroenterology."},{"key":"263_CR10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.gastro.2016.10.020","volume":"152","author":"GG Kaplan","year":"2017","unstructured":"Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017;152:313\u201321.","journal-title":"Gastroenterology."},{"key":"263_CR11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/his.12263","volume":"64","author":"RM Feakins","year":"2014","unstructured":"Feakins RM. Ulcerative colitis or Crohn\u2019s disease? Pitfalls and problems. Histopathology. 2014;64:317\u201335.","journal-title":"Histopathology."},{"key":"263_CR12","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","volume":"55","author":"J Satsangi","year":"2006","unstructured":"Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749\u201353.","journal-title":"Gut."},{"key":"263_CR13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/01.pas.0000189178.00440.bf","volume":"30","author":"RK Yantiss","year":"2006","unstructured":"Yantiss RK, Farraye FA, O\u2019Brien MJ, Fruin AB, Stucchi AF, Becker JM, et al. Prognostic significance of superficial fissuring ulceration in patients with severe \u201cindeterminate\u201d colitis. Am J Surg Pathol. 2006;30:165\u201370.","journal-title":"Am J Surg Pathol."},{"key":"263_CR14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature10209","volume":"474","author":"B Khor","year":"2011","unstructured":"Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307\u201317.","journal-title":"Nature."},{"issue":"12","key":"263_CR15","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.crohns.2014.08.011","volume":"8","author":"R.V. Bryant","year":"2014","unstructured":"Bryant RV, Winer S, Travis SP, Riddell RH. Systematic review: histological remission in inflammatory bowel disease. Is \u2018complete\u2019 remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis. 2014;8:1582\u201397.","journal-title":"Journal of Crohn's and Colitis"},{"key":"263_CR16","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/MIB.0b013e318280b19e","volume":"19","author":"S Plevy","year":"2013","unstructured":"Plevy S, Silverberg MS, Lockton S, Stockfisch T, Croner L, Stachelski J, et al. Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn\u2019s disease, and ulcerative colitis patients. Inflamm Bowel Dis. 2013;19:1139\u201348.","journal-title":"Inflamm Bowel Dis."},{"key":"263_CR17","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/apt.12671","volume":"39","author":"M Ellrichmann","year":"2014","unstructured":"Ellrichmann M, Wietzke-Braun P, Dhar S, Nikolaus S, Arlt A, Bethge J, et al. Endoscopic ultrasound of the colon for the differentiation of Crohn\u2019s disease and ulcerative colitis in comparison with healthy controls. Aliment Pharmacol Ther. 2014;39:823\u201333.","journal-title":"Aliment Pharmacol Ther."},{"key":"263_CR18","first-page":"226","volume":"12","author":"P Deepak","year":"2016","unstructured":"Deepak P, Kolbe AB, Fidler JL, Fletcher JG, Knudsen JM, Bruining DH. Update on magnetic resonance imaging and ultrasound evaluation of Crohn\u2019s disease. Gastroenterol Hepatol (N Y). 2016;12:226\u201336.","journal-title":"Gastroenterol Hepatol (N Y)."},{"key":"263_CR19","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0016-5107(95)70097-8","volume":"42","author":"CN Bernstein","year":"1995","unstructured":"Bernstein CN, Shanahan F, Anton PA, Weinstein WM. Patchiness of mucosal inflammation in treated ulcerative colitis: a prospective study. Gastrointest Endosc. 1995;42:232\u20137.","journal-title":"Gastrointest Endosc."},{"key":"263_CR20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/gastro\/gou028","volume":"2","author":"ER Paine","year":"2014","unstructured":"Paine ER. Colonoscopic evaluation in ulcerative colitis. Gastroenterol Rep (Oxf). 2014;2:161\u20138.","journal-title":"Gastroenterol Rep (Oxf)."},{"key":"263_CR21","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/gastro\/gou031","volume":"2","author":"TC DeRoche","year":"2014","unstructured":"DeRoche TC, Xiao SY, Liu X. Histological evaluation in ulcerative colitis. Gastroenterol Rep (Oxf). 2014;2:178\u201392.","journal-title":"Gastroenterol Rep (Oxf)."},{"key":"263_CR22","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/MIB.0b013e3182802893","volume":"19","author":"E Sinakos","year":"2013","unstructured":"Sinakos E, Samuel S, Enders F, Loftus EV Jr, Sandborn WJ, Lindor KD. Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship. Inflamm Bowel Dis. 2013;19:1004\u20139.","journal-title":"Inflamm Bowel Dis."},{"key":"263_CR23","first-page":"308","volume":"93","author":"P Lecis","year":"2002","unstructured":"Lecis P, German\u00e0 B, Papa N, Bertiato G, Doglioni C, Galliani E, et al. p-ANCA and ASCA antibodies in the differential diagnosis between ulcerative rectocolitis and Crohn\u2019s disease (in Italian). Recent Prog Med. 2002;93:308\u201313.","journal-title":"Recent Prog Med"},{"key":"263_CR24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1006\/clim.2001.5145","volume":"102","author":"J Bartunkov\u00e1","year":"2002","unstructured":"Bartunkov\u00e1 J, Kol\u00e1rov\u00e1 I, Sediv\u00e1 A, H\u00f6lzelov\u00e1 E. Antineutrophil cytoplasmic antibodies, anti-Saccharomyces cerevisiae antibodies, and specific IgE to food allergens in children with inflammatory bowel diseases. Clin Immunol. 2002;102:162\u20138.","journal-title":"Clin Immunol."},{"key":"263_CR25","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1053\/gast.1996.v110.pm8964407","volume":"110","author":"EA Vasiliauskas","year":"1996","unstructured":"Vasiliauskas EA, Plevy SE, Landers CJ, Binder SW, Ferguson DM, Yang H, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn\u2019s disease define a clinical subgroup. Gastroenterology. 1996;110:1810\u20139.","journal-title":"Gastroenterology."},{"key":"263_CR26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/bjs.5464","volume":"94","author":"D Hahnloser","year":"2007","unstructured":"Hahnloser D, Pemberton JH, Wolff BG, Larson DR, Crownhart BS, Dozois RR. Results at up to 20 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Br J Surg. 2007;94:333\u201340.","journal-title":"Br J Surg."},{"key":"263_CR27","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00384-010-0915-8","volume":"25","author":"H Ikeuchi","year":"2010","unstructured":"Ikeuchi H, Uchino M, Matsuoka H, Bando T, Matsumoto T, Tomita N, et al. Surgery for ulcerative colitis in 1,000 patients. Int J Colorectal Dis. 2010;25:959\u201365.","journal-title":"Int J Colorectal Dis."},{"key":"263_CR28","doi-asserted-by":"crossref","unstructured":"Caviglia GP, Dughera F, Ribaldone DG, Rosso C, Abate ML, Pellicano R, et al. Serum zonulin in patients with inflammatory bowel disease: a pilot study. Minerva Med. \n                    http:\/\/doi.org\/10.23736\/S0026-4806.18.05787-7\n                    \n                   (epub 28 Aug 2018).","DOI":"10.23736\/S0026-4806.18.05787-7"},{"key":"263_CR29","doi-asserted-by":"crossref","first-page":"e56818","DOI":"10.1371\/journal.pone.0056818","volume":"8","author":"A Granlund","year":"2013","unstructured":"Granlund A, Flatberg A, \u00d8stvik AE, Drozdov I, Gustafsson BI, Kidd M, et al. Whole genome gene expression meta-analysis of inflammatory bowel disease colon mucosa demonstrates lack of major differences between Crohn\u2019s disease and ulcerative colitis. PLoS One. 2013;8:e56818.","journal-title":"PLoS One."},{"key":"263_CR30","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/ibd.21579","volume":"17","author":"M Waterman","year":"2011","unstructured":"Waterman M, Xu W, Stempak JM, Milgrom R, Bernstein CN, Griffiths AM, et al. Distinct and overlapping genetic loci in Crohn\u2019s disease and ulcerative colitis: correlations with pathogenesis. Inflamm Bowel Dis. 2011;17:1936\u201342.","journal-title":"Inflamm Bowel Dis."},{"key":"263_CR31","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/ng.764","volume":"43","author":"CA Anderson","year":"2011","unstructured":"Anderson CA, Boucher G, Lees CW, Franke A, D\u2019Amato M, Taylor KD, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43:246\u201352.","journal-title":"Nat Genet."},{"key":"263_CR32","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(15)00465-1","volume":"387","author":"I Cleynen","year":"2016","unstructured":"Cleynen I, Boucher G, Jostins L, Schumm LP, Zeissig S, Ahmad T, et al. Inherited determinants of Crohn\u2019s disease and ulcerative colitis phenotypes: a genetic association study. Lancet. 2016;387:156\u201367.","journal-title":"Lancet."},{"key":"263_CR33","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.autrev.2014.01.028","volume":"13","author":"K Conrad","year":"2014","unstructured":"Conrad K, Roggenbuck D, Laass MW. Diagnosis and classification of ulcerative colitis. Autoimmun Rev. 2014;13:463\u20136.","journal-title":"Autoimmun Rev."},{"key":"263_CR34","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","volume":"2","author":"SC Truelove","year":"1955","unstructured":"Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041\u20138.","journal-title":"Br Med J."},{"issue":"7","key":"263_CR35","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","volume":"11","author":"Marcus Harbord","year":"2017","unstructured":"Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current management. J Crohns Colitis. 2017;11:769\u201384.","journal-title":"Journal of Crohn's and Colitis"},{"key":"263_CR36","doi-asserted-by":"crossref","unstructured":"Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501\u201323.","DOI":"10.1038\/ajg.2009.727"},{"key":"263_CR37","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.2010.224154","volume":"60","author":"C Mowat","year":"2011","unstructured":"Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571\u2013607.","journal-title":"Gut."},{"key":"263_CR38","unstructured":"National Institute for Health and Care Excellence. Ulcerative colitis: management. 2016. \n                    https:\/\/www.nice.org.uk\/guidance\/cg166\/resources\/ulcerative-colitis-management-35109695126725\n                    \n                  . Accessed 25 Jan 2019."},{"key":"263_CR39","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/j.gastro.2015.05.036","volume":"149","author":"T Dassopoulos","year":"2015","unstructured":"Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD. Ulcerative colitis care pathway. Gastroenterology. 2015;149:238\u201345.","journal-title":"Gastroenterology."},{"key":"263_CR40","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462\u201376.","journal-title":"N Engl J Med."},{"key":"263_CR41","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1365-2036.2010.04531.x","volume":"33","author":"C Taxonera","year":"2011","unstructured":"Taxonera C, Estell\u00e9s J, Fern\u00e1ndez-Blanco I, Merino O, Mar\u00edn-Jim\u00e9nez I, Barreiro-de AM, et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther. 2011;33:340\u20138.","journal-title":"Aliment Pharmacol Ther."},{"key":"263_CR42","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367:616\u201324.","journal-title":"N Engl J Med."},{"key":"263_CR43","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1097\/MIB.0000000000000787","volume":"22","author":"N Manetti","year":"2016","unstructured":"Manetti N, Bagnoli S, Rogai F, Bonanomi AG, Vannozzi G, Giannotta M, et al. Disease course and colectomy rate of ulcerative colitis: a follow-up cohort study of a referral center in Tuscany. Inflamm Bowel Dis. 2016;22:1945\u201353.","journal-title":"Inflamm Bowel Dis."},{"key":"263_CR44","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/2050640616679552","volume":"5","author":"S Sahami","year":"2017","unstructured":"Sahami S, Kont\u00e9 K, Buskens CJ, Tanis PJ, L\u00f6wenberg M, Ponsioen CJ, et al. Risk factors for proximal disease extension and colectomy in left-sided ulcerative colitis. United Eur Gastroenterol J. 2017;5:554\u201362.","journal-title":"United Eur Gastroenterol J."},{"key":"263_CR45","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/00365520802600961","volume":"44","author":"IC Solberg","year":"2009","unstructured":"Solberg IC, Lygren I, Jahnsen J, Aadland E, H\u00f8ie O, Cvancarova M, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431\u201340.","journal-title":"Scand J Gastroenterol."},{"key":"263_CR46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/1756283X10361304","volume":"3","author":"E Langholz","year":"2010","unstructured":"Langholz E. Current trends in inflammatory bowel disease: the natural history. Therap Adv Gastroenterol. 2010;3:77\u201386.","journal-title":"Therap Adv Gastroenterol."},{"key":"263_CR47","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/ibd.20897","volume":"15","author":"MJ Etchevers","year":"2009","unstructured":"Etchevers MJ, Aceituno M, Garc\u00eda-Bosch O, Ord\u00e1s I, Sans M, Ricart E, et al. Risk factors and characteristics of extent progression in ulcerative colitis. Inflamm Bowel Dis. 2009;15:1320\u20135.","journal-title":"Inflamm Bowel Dis."},{"key":"263_CR48","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756\u201370.","journal-title":"Lancet."},{"key":"263_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2036.18.s2.2.x","volume":"18","author":"P Munkholm","year":"2003","unstructured":"Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:1\u20135.","journal-title":"Aliment Pharmacol Ther."},{"key":"263_CR50","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/gut.48.4.526","volume":"48","author":"JA Eaden","year":"2001","unstructured":"Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526\u201335.","journal-title":"Gut."},{"issue":"6","key":"263_CR51","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","volume":"11","author":"Fernando Magro","year":"2017","unstructured":"Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11:649\u201370.","journal-title":"Journal of Crohn's and Colitis"},{"key":"263_CR52","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1053\/j.gastro.2005.12.035","volume":"130","author":"MD Rutter","year":"2006","unstructured":"Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130:1030\u20138.","journal-title":"Gastroenterology."},{"key":"263_CR53","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/apt.12651","volume":"39","author":"C Casta\u00f1o-Milla","year":"2014","unstructured":"Casta\u00f1o-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther. 2014;39:645\u201359.","journal-title":"Aliment Pharmacol Ther."},{"key":"263_CR54","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1457496916659224","volume":"106","author":"M Ruteg\u00e5rd","year":"2017","unstructured":"Ruteg\u00e5rd M, Palmqvist R, Stenling R, Lindberg J, Ruteg\u00e5rd J. Efficiency of colorectal cancer surveillance in patients with ulcerative colitis: 38 years\u2019 experience in a patient cohort from a defined population area. Scand J Surg. 2017;106:133\u20138.","journal-title":"Scand J Surg."},{"key":"263_CR55","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ajg.2015.65","volume":"110","author":"CH Choi","year":"2015","unstructured":"Choi CH, Rutter MD, Askari A, Lee GH, Warusavitarne J, Moorghen M, et al. Forty-year analysis of colonoscopic surveillance program for neoplasia in ulcerative colitis: an updated overview. Am J Gastroenterol. 2015;110:1022\u201334.","journal-title":"Am J Gastroenterol."},{"key":"263_CR56","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/gastro\/gou070","volume":"3","author":"Z Arora","year":"2015","unstructured":"Arora Z, Shen B. Biological therapy for ulcerative colitis. Gastroenterol Rep (Oxf). 2015;3:103\u20139.","journal-title":"Gastroenterol Rep (Oxf)."},{"key":"263_CR57","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/gut.26.2.146","volume":"26","author":"V Binder","year":"1985","unstructured":"Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn\u2019s disease-based on results from a regional patient group from the county of Copenhagen. Gut. 1985;26:146\u201350.","journal-title":"Gut."},{"key":"263_CR58","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1002\/1097-0142(19811215)48:12<2742::AID-CNCR2820481231>3.0.CO;2-P","volume":"48","author":"AJ Greenstein","year":"1981","unstructured":"Greenstein AJ, Sachar DB, Smith H, Janowitz HD, Aufses AH Jr. A comparison of cancer risk in Crohn\u2019s disease and ulcerative colitis. Cancer. 1981;48:2742\u20135.","journal-title":"Cancer."},{"key":"263_CR59","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/MOG.0b013e32836229fb","volume":"29","author":"J Burisch","year":"2013","unstructured":"Burisch J, Munkholm P. Inflammatory bowel disease epidemiology. Curr Opin Gastroenterol. 2013;29:357\u201362.","journal-title":"Curr Opin Gastroenterol."},{"key":"263_CR60","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/MIB.0b013e31828029c0","volume":"19","author":"MW Lutgens","year":"2013","unstructured":"Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 2013;19:789\u201399.","journal-title":"Inflamm Bowel Dis."},{"key":"263_CR61","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1053\/j.gastro.2015.01.031","volume":"148","author":"L Laine","year":"2015","unstructured":"Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology. 2015;148:639\u201351.","journal-title":"Gastroenterology."},{"key":"263_CR62","unstructured":"National Institute for Health and Care Excellence. Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn\u2019s disease or adenomas. 2011. \n                    https:\/\/www.nice.org.uk\/guidance\/cg118\n                    \n                  . Accessed 25 Jan 2019."},{"issue":"1337\u201344","key":"263_CR63","first-page":"e3","volume":"152","author":"RW Leong","year":"2017","unstructured":"Leong RW, Ooi M, Corte C, Yau Y, Kermeen M, Katelaris PH, et al. Full-spectrum endoscopy improves surveillance for dysplasia in patients with inflammatory bowel diseases. Gastroenterology. 2017;152(1337\u201344):e3.","journal-title":"Gastroenterology."},{"key":"263_CR64","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.cgh.2016.11.021","volume":"15","author":"A Iannone","year":"2017","unstructured":"Iannone A, Ruospo M, Wong G, Principi M, Barone M, Strippoli GF, et al. Chromoendoscopy for surveillance in ulcerative colitis and Crohn\u2019s disease: a systematic review of randomized trials. Clin Gastroenterol Hepatol. 2017;15:1684\u201397.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"263_CR65","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","volume":"11","author":"F Gomoll\u00f3n","year":"2017","unstructured":"Gomoll\u00f3n F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: Part 1: Diagnosis and medical management. J Crohns Colitis. 2017;11:3\u201325.","journal-title":"J Crohns Colitis."},{"key":"263_CR66","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/CEG.S57248","volume":"8","author":"HMW Khan","year":"2015","unstructured":"Khan HMW, Mehmood F, Khan N. Optimal management of steroid-dependent ulcerative colitis. Clin Exp Gastroenterol. 2015;8:293\u2013302.","journal-title":"Clin Exp Gastroenterol."},{"key":"263_CR67","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/gut.2005.068809","volume":"55","author":"S Ardizzone","year":"2006","unstructured":"Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47\u201353.","journal-title":"Gut."},{"key":"263_CR68","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/gut.50.4.485","volume":"50","author":"AG Fraser","year":"2002","unstructured":"Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50:485\u20139.","journal-title":"Gut."},{"key":"263_CR69","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/00042737-200012110-00010","volume":"12","author":"J Mat\u00e9-Jim\u00e9nez","year":"2000","unstructured":"Mat\u00e9-Jim\u00e9nez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12:1227\u201333.","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"Supplement 3","key":"263_CR70","doi-asserted-by":"crossref","first-page":"iii43","DOI":"10.1136\/gut.50.suppl_3.iii43","volume":"50","author":"M Campieri","year":"2002","unstructured":"Campieri M. New steroids and new salicylates in inflammatory bowel disease: a critical appraisal. Gut. 2002;50:III43\u20136.","journal-title":"Gut"},{"key":"263_CR71","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.dld.2016.02.024","volume":"48","author":"J Lla\u00f3","year":"2016","unstructured":"Lla\u00f3 J, Naves JE, Ruiz-Cerulla A, Gordillo J, Ma\u00f1osa M, Maisterra S, et al. Improved outcome of acute severe ulcerative colitis while using early predictors of corticosteroid failure and rescue therapies. Dig Liver Dis. 2016;48:608\u201312.","journal-title":"Dig Liver Dis."},{"key":"263_CR72","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/apt.12727","volume":"39","author":"DT Rubin","year":"2014","unstructured":"Rubin DT, Mody R, Davis KL, Wang CC. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn\u2019s disease. Aliment Pharmacol Ther. 2014;39:1143\u201355.","journal-title":"Aliment Pharmacol Ther."},{"key":"263_CR73","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1542-3565(03)00185-X","volume":"1","author":"EV Loftus Jr","year":"2003","unstructured":"Loftus EV Jr, Achenbach SJ, Sandborn WJ, Tremaine WJ, Oberg AL, Melton LJ 3rd. Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2003;1:465\u201373.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"263_CR74","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/apt.14334","volume":"46","author":"CP Selinger","year":"2017","unstructured":"Selinger CP, Parkes GC, Bassi A, Fogden E, Hayee B, Limdi JK, et al. A multi-centre audit of excess steroid use in 1176 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46:964\u201373.","journal-title":"Aliment Pharmacol Ther."},{"key":"263_CR75","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s12325-016-0393-7","volume":"33","author":"K Lasch","year":"2016","unstructured":"Lasch K, Liu S, Ursos L, Mody R, King-Concialdi K, DiBonaventura M, et al. Gastroenterologists\u2019 perceptions regarding ulcerative colitis and its management: results from a large-scale survey. Adv Ther. 2016;33:1715\u201327.","journal-title":"Adv Ther."},{"key":"263_CR76","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1177\/1756283X16643242","volume":"9","author":"MA Sofia","year":"2016","unstructured":"Sofia MA, Rubin DT. Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis. Ther Adv Gastroenterol. 2016;9:548\u201359.","journal-title":"Ther Adv Gastroenterol."},{"key":"263_CR77","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11894-015-0453-1","volume":"17","author":"A O\u2019Toole","year":"2015","unstructured":"O\u2019Toole A, Moss AC. Optimizing biologic agents in ulcerative colitis and Crohn\u2019s disease. Curr Gastroenterol Rep. 2015;17:32.","journal-title":"Curr Gastroenterol Rep."},{"key":"263_CR78","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/01.MIB.0000437498.14804.50","volume":"20","author":"M Bewtra","year":"2014","unstructured":"Bewtra M, Kilambi V, Fairchild AO, Siegel CA, Lewis JD, Johnson FR. Patient preferences for surgical versus medical therapy for ulcerative colitis. Inflamm Bowel Dis. 2014;20:103\u201314.","journal-title":"Inflamm Bowel Dis."},{"key":"263_CR79","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/codi.12538","volume":"16","author":"CM Byrne","year":"2014","unstructured":"Byrne CM, Tan KK, Young JM, Selby W, Solomon MJ. Patient and clinician preferences for surgical and medical treatment options in ulcerative colitis. Colorectal Dis. 2014;16:285\u201392.","journal-title":"Colorectal Dis."},{"key":"263_CR80","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/01.MIB.0000436277.13917.c4","volume":"20","author":"J Burisch","year":"2014","unstructured":"Burisch J, Pedersen N, Cukovic-Cavka S, Turk N, Kaimakliotis I, Duricova D, et al. Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort. Inflamm Bowel Dis. 2014;20:36\u201346.","journal-title":"Inflamm Bowel Dis."},{"key":"263_CR81","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/ajg.2014.242","volume":"109","author":"JF Colombel","year":"2014","unstructured":"Colombel JF, Sandborn WJ, Ghosh S, Wolf DC, Panaccione R, Feagan B, et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014;109:1771\u201380.","journal-title":"Am J Gastroenterol."},{"issue":"96\u2013109","key":"263_CR82","first-page":"e1","volume":"146","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(96\u2013109):e1.","journal-title":"Gastroenterology."},{"key":"263_CR83","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699\u2013710.","journal-title":"N Engl J Med."},{"key":"263_CR84","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.13847","volume":"45","author":"EJ Mao","year":"2017","unstructured":"Mao EJ, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn\u2019s disease and ulcerative colitis. Aliment Pharmacol Ther. 2017;45:3\u201313.","journal-title":"Aliment Pharmacol Ther."},{"key":"263_CR85","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ajg.2011.60","volume":"106","author":"V Billioud","year":"2011","unstructured":"Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn\u2019s disease: a systematic review. Am J Gastroenterol. 2011;106:674\u201384.","journal-title":"Am J Gastroenterol."},{"key":"263_CR86","first-page":"760","volume":"104","author":"JP Gisbert","year":"2009","unstructured":"Gisbert JP, Pan\u00e9s J. Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: a review. Am J Gastroenterol. 2009;104:760\u20137.","journal-title":"Am J Gastroenterol."},{"key":"263_CR87","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/ecco-jcc\/jjv061","volume":"9","author":"X Roblin","year":"2015","unstructured":"Roblin X, Marotte H, Leclerc M, Del Tedesco E, Phelip JM, Peyrin-Biroulet L, et al. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease. J Crohns Colitis. 2015;9:525\u201331.","journal-title":"J Crohns Colitis."},{"key":"263_CR88","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","volume":"72","author":"FB Vincent","year":"2013","unstructured":"Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72:165\u201378.","journal-title":"Ann Rheum Dis."},{"key":"263_CR89","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/gutjnl-2014-307882","volume":"65","author":"F Baert","year":"2016","unstructured":"Baert F, Kondragunta V, Lockton S, Vande Casteele N, Hauenstein S, Singh S, et al. Antibodies to adalimumab are associated with future inflammation in Crohn\u2019s patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial. Gut. 2016;65:1126\u201331.","journal-title":"Gut."},{"key":"263_CR90","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ajg.2012.363","volume":"108","author":"KS Nanda","year":"2013","unstructured":"Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108:40\u20137.","journal-title":"Am J Gastroenterol."},{"key":"263_CR91","first-page":"556","volume":"13","author":"A Cheifetz","year":"2017","unstructured":"Cheifetz A. Overview of therapeutic drug monitoring of biologic agents in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2017;13:556\u20139.","journal-title":"Gastroenterol Hepatol (N Y)."},{"key":"263_CR92","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/apt.13994","volume":"45","author":"AS Strik","year":"2017","unstructured":"Strik AS, van den Brink GR, Ponsioen C, Mathot R, L\u00f6wenberg M, D\u2019Haens GR. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:1128\u201334.","journal-title":"Aliment Pharmacol Ther."},{"key":"263_CR93","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1097\/MIB.0000000000001145","volume":"23","author":"LA Feagins","year":"2017","unstructured":"Feagins LA, Waljee A, Hou JK, Gu P, Kanjo S, Rudrapatna V, et al. Incidence of and predictors for early discontinuation of biological therapies in veteran patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:1434\u20139.","journal-title":"Inflamm Bowel Dis."},{"key":"263_CR94","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/apt.13736","volume":"44","author":"S Bek","year":"2016","unstructured":"Bek S, Nielsen JV, Bojesen AB, Franke A, Bank S, Vogel U, et al. Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;44:554\u201367.","journal-title":"Aliment Pharmacol Ther."},{"key":"263_CR95","first-page":"243","volume":"29","author":"B Ungar","year":"2016","unstructured":"Ungar B, Kopylov U. Advances in the development of new biologics in inflammatory bowel disease. Ann Gastroenterol. 2016;29:243\u20138.","journal-title":"Ann Gastroenterol."},{"key":"263_CR96","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00535-016-1283-0","volume":"52","author":"HC Chan","year":"2017","unstructured":"Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2017;52:141\u201350.","journal-title":"J Gastroenterol."},{"key":"263_CR97","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s12328-016-0686-z","volume":"9","author":"M Naganuma","year":"2016","unstructured":"Naganuma M, Mizuno S, Nanki K, Sugimoto S, Kanai T. Recent trends and future directions for the medical treatment of ulcerative colitis. Clin J Gastroenterol. 2016;9:329\u201336.","journal-title":"Clin J Gastroenterol."},{"key":"263_CR98","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/1744666X.2017.1291342","volume":"13","author":"P Olivera","year":"2017","unstructured":"Olivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in inflammatory bowel disease. Expert Rev Clin Immunol. 2017;13:693\u2013703.","journal-title":"Expert Rev Clin Immunol."},{"key":"263_CR99","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12876-015-0239-9","volume":"15","author":"J Pan\u00e9s","year":"2015","unstructured":"Pan\u00e9s J, Su C, Bushmakin AG, Cappelleri JC, Mamolo C, Healey P. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes. BMC Gastroenterol. 2015;15:14.","journal-title":"BMC Gastroenterol."},{"key":"263_CR100","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, D\u2019Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723\u201336.","journal-title":"N Engl J Med."},{"key":"263_CR101","first-page":"2106","volume":"24","author":"S Danese","year":"2018","unstructured":"Danese S, D\u2019Amico F, Bonovas S, Peyrin-Biroulet L. Positioning tofacitinib in the treatment algorithm of moderate to severe ulcerative colitis. Inflamm Bowel Dis. 2018;24:2106\u201312.","journal-title":"Inflamm Bowel Dis."},{"key":"263_CR102","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cgh.2018.07.009","volume":"17","author":"S Hanauer","year":"2019","unstructured":"Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, Higgins PDR, et al. Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2019;17:139\u201347.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"263_CR103","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","volume":"374","author":"WJ Sandborn","year":"2016","unstructured":"Sandborn WJ, Feagan BG, Wolf DC, D\u2019Haens G, Vermeire S, Hanauer SB, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016;374:1754\u201362.","journal-title":"N Engl J Med."},{"key":"263_CR104","doi-asserted-by":"crossref","unstructured":"Imdad A, Nicholson MR, Tanner-Smith EE, Zackular JP, Gomez-Duarte OG, Beaulieu DB, et al. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev. 2018;11:CD012774.","DOI":"10.1002\/14651858.CD012774.pub2"},{"key":"263_CR105","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/MOG.0000000000000285","volume":"32","author":"P Moayyedi","year":"2016","unstructured":"Moayyedi P. Fecal transplantation: any real hope for inflammatory bowel disease? Curr Opin Gastroenterol. 2016;32:282\u20136.","journal-title":"Curr Opin Gastroenterol."}],"container-title":["Drugs in R&amp;D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-019-0263-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-019-0263-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-019-0263-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T19:28:23Z","timestamp":1583004503000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-019-0263-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,2]]},"references-count":105,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["263"],"URL":"https:\/\/doi.org\/10.1007\/s40268-019-0263-2","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,2]]},"assertion":[{"value":"2 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This article was funded by Pfizer Inc, New York, NY, USA. The article processing charge for open access was funded by Pfizer Inc, New York, NY, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Geert R.A.M. D\u2019Haens has received consulting fees from AbbVie, Ablynx, Amakem, AM Pharma, Avaxia, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cosmo, Covidien\/Medtronics, Dr. Falk Pharma, Engene, Ferring, Galapagos, Gilead, GlaxoSmithKline, Hospira, Immunic, Johnson and Johnson, Lycera, Medimetrics, Millennium\/Takeda, Mitsubishi Pharma, MSD, Mundipharma, Novo Nordisk, Pfizer Inc, Prometheus Laboratories\/Nestle, Receptos, Robarts Clinical Trials, Salix, Sandoz, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, Versant, and Vifor; research grants from AbbVie, Falk, Ferring, MSD, Mundipharma, and Takeda; and lecture and\/or speaker bureau fees from AbbVie, Ferring, Johnson and Johnson, Millennium\/Takeda, MSD, Mundipharma, Norgine, Pfizer Inc, Shire, Tillotts, and Vifor. James O. Lindsay has received consulting fees from AbbVie, Celgene, Ferring, Janssen, Merck, Pfizer Inc, Robarts Clinical Trials, Shire, and Takeda; research grants from Pfizer Inc\/Hospira, MSD, Shire, and Takeda; lecture and\/or speaker bureau fees from AbbVie, Allergan, Ferring, Janssen, MSD, Shire, and Takeda; and advisory board fees from AbbVie, Atlantic Healthcare, Ferring, Hospira, Janssen, MSD, NAP, Pfizer Inc, Shire, Takeda, and Vifor. Remo Panaccione has received consulting fees from AbbVie, Amgen, Aptalis, AstraZeneca, Baxter, Biogen, Bristol-Myers Squibb, Celgene, Centocor, Cubist, Eisai, Elan, Ferring, Gilead, GlaxoSmithKline, Janssen, Merck, Pfizer Inc, Robarts Clinical Trials, Salix, Samsung Bioepis, Shire, Takeda, and UCB; research grants from AbbVie, Ferring, Janssen, and Takeda; lecture and\/or speaker bureau fees from AbbVie, Aptalis, AstraZeneca, Ferring, Janssen, Merck, Prometheus, Shire, and Takeda; and advisory board fees from Abbott, AbbVie, Amgen, Aptalis, AstraZeneca, Baxter, Bristol-Myers Squibb, Celgene, Centocor, Cubist, Eisai, Elan, Ferring, Genentech, GlaxoSmithKline, Janssen, Merck, Pfizer Inc, Salix, Schering-Plough, Shire, Takeda, and UCB. Stefan Schreiber has received consulting fees from AbbVie, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Galapagos, Janssen, MedImmune, MSD, Pfizer Inc\/Hospira, Shire, Takeda, and UCB; and lecture and\/or speaker bureau fees from AbbVie, Falk, Ferring, MSD, Takeda, and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}